Professor of Radiation Oncology, Va Commonwealth University School of Medicine
Radiation Oncology
Dr. Mitchell S. Anscher, MD
|
|
Give Review
Dr. Mitchell S. Anscher works in the field of Radiation Oncology. He researched medicine at Virginia Commonwealth University School of Medicine. He has 2 awards "America's Top Doctors for Cancer" and "America's Top Doctors". Dr. Mitchell S. Anscher is a published doctor and has 74 publications published. The lastest was: 'ReCAP: Time-Driven Activity-Based Costing: A Comparative Cost Analysis of Whole-Breast Radiotherapy Versus Balloon-Based Brachytherapy in the Management of Early-Stage...' Doctor Mitchell S. Anscher, MD is registered with Medicare and accepts Medicare payments.
Publications
- Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.
- A Preliminary Study on Racial Differences in HMOX1, NFE2L2, and TGFβ1 Gene Polymorphisms and Radiation-Induced Late Normal Tissue Toxicity.
- Clinic Offering Affordable Radiation Therapy to Increase Access to Care for Patients Enrolled in Hospice.
- Availability of Single-Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care within the Veterans Healthcare Administration.
- Examining the relationship between pre- and postimplant geometry in prostate LDR brachytherapy and its correlation with dosimetric quality using the similarity concept.
- Prostate Cancer treatment and survival: evidence for men with prevalent comorbid conditions.
- Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey.
- Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society f...
- Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate Cancer.
- Prostate Cancer: Should men with metastases undergo radical prostatectomy?
- Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate Cancer: A population-based analysis.
- Identifying Appropriate Patients for Early Salvage Radiotherapy after Prostatectomy.
- Physical activity and sedentary behavior of Cancer survivors and non-Cancer individuals: results from a national survey.
- Self-referral in radiation oncology: has caveat emptor replaced primum non nocere?
- Accelerated partial-breast irradiation: trial by media or by science?
- Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy.
- Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the pro...
- Moving Toward Focal Therapy in Prostate Cancer: Dual-Isotope Permanent Seed Implants as a Possible Solution.
- Salvage radiation in men after prostate-specific antigen failure and the risk of death.
- Proteomic analysis of radiation-induced changes in rat lung: Modulation by the superoxide dismutase mimetic MnTE-2-PyP(5+).
- Radiation pulmonary toxicity: from mechanisms to management.
- Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate Cancer.
- The negative impact of stark law exemptions on graduate medical education and health care costs: the example of radiation oncology.
- Targeting the TGF-beta1 pathway to prevent normal tissue injury after Cancer therapy.
- Comparisons of treatment optimization directly incorporating random patient setup uncertainty with a margin-based approach.
- ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate Cancer expert panel on radiation oncology--prostate.
- Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate...
- A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate Cancer.
- Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury.
- Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate Cancer.
- Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate Cancer.
- Technical evaluation of radiation dose delivered in prostate Cancer patients as measured by an implantable MOSFET dosimeter.
- Predicting the outcome of salvage radiation therapy for recurrent prostate Cancer after radical prostatectomy.
- Rectourethral fistula after combination radiotherapy for prostate Cancer.
- Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury.
- Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate Cancer screening.
- Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
- Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung Cancer?
- Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation.
- Radiation therapy in the treatment of cholangiocarcinoma.
- Medical malpractice in the age of technology: how specialty societies can make a difference.
- Cytokine profiling for prediction of symptomatic radiation-induced lung injury.
- Radiotherapy for locally recurrent prostate Cancer.
- The irreversibility of radiation-induced fibrosis: fact or folklore?
- A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness.
- An analysis of an implantable dosimeter system for external beam therapy.
- Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting.
- PSA kinetics and risk of death from prostate Cancer: in search of the Holy Grail of surrogate end points.
- Initial clinical results of an in vivo dosimeter during external beam radiation therapy.
- Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy.
- Mechanisms and potential targets for prevention and treatment of normal tissue injury after radiation therapy.
- In regard to De Jaeger et al.: significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung Cancer (INT J RADIAT ONCOL BIOL PH...
- Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung Cancer?
- Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003.
- The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats.
- Prostatectomy vs brachytherapy for localized prostate Cancer.
- Comparing radical prostatectomy and brachytherapy for localized prostate Cancer.
- Salvage radiotherapy for recurrent prostate Cancer: the earlier the better.
- A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
- Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury.
- Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats.
- Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.
- Normal tissue effects: reporting and analysis.
- Radiation-induced lung injury.
- Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
- A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury.
- Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity.
- Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy.
- The time course of radiation therapy-induced reductions in regional perfusion: a prospective study with >5 years of follow-up.
- Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years.
- A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, un...
- Serial Evaluation of Increased Chest Wall F-18 Fluorodeoxyglucose (FDG) Uptake Following Radiation Therapy in Patients With Bronchogenic Carcinoma.
- ReCAP: Time-Driven Activity-Based Costing: A Comparative Cost Analysis of Whole-Breast Radiotherapy Versus Balloon-Based Brachytherapy in the Management of Early-Stage...
Schools
Virginia Commonwealth University School Of Medicine
St MaryS Hospital
Duke University Med Center
Conditions Treated
- Pituitary Gland Cancer
- Vulvar Cancer
Doctors Specialties
- Internal Medicine
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors for Cancer
- America's Top Doctors
Education
-
Duke University Hospital -
Virginia Commonwealth University School of Medicine
Drug Facts
| NPI NUMBER | 1366472102 | |
| NPPES Provider LastName | ANSCHER | |
| NPPES Provider FirstName | MITCHELL | |
| NPPES Provider ZIPCode | 232980058 | |
| NPPES Provider State | VA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 28.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1366472102 |
| Last Name Of The Provider | ANSCHER |
| First Name Of The Provider | MITCHELL |
| View All |
Similar Doctors
|
|
Dr. Olubunmi K. Abayomi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter J. Stefanik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leslie W. Rose III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nana A. Owusu-Nyamekye, MD |
|
|
Dr. Michael T. Liu, MD |
|
|
Dr. Lauren C. Paulk, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Laurie W. Cuttino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Drew Moghanaki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael G. Chang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry Lomas IV, MD |
|
|
Dr. Emma C. Fields, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marcus W. Brown, MD |
|
|
Dr. Nathan B. Tennyson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Randolph II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas A. Serrano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elisabeth Weiss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alfredo I. Urdaneta, MD
This Doctor is OpenDoctor Recommended.
|